Unlock instant, AI-driven research and patent intelligence for your innovation.

Telaprevir intermediate and preparation method thereof

A telaprevir and intermediate technology, applied in the field of drug synthesis, can solve problems such as inability to produce sustained virological response and adverse reactions

Active Publication Date: 2015-01-21
SHANGHAI INST OF PHARMA IND +2
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The current treatment for chronic hepatitis C is mainly the combination of pegylated interferon (PEG-IFNα) and ribavirin (RBV), which fails to produce a sustained virological response in about 50% of HCV type I patients , and have adverse reactions, so it is urgent to develop effective therapeutic drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Telaprevir intermediate and preparation method thereof
  • Telaprevir intermediate and preparation method thereof
  • Telaprevir intermediate and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] Preparation of Compound C (according to the method in J.Org.Chem., Vol.59, No.10, 1994):

[0072]

[0073] At 20°C, add 4-methyl-5-hydroxyethylthiazole (40g, 0.27mol), ethyl bromoacetate (37.1ml, 0.33mol), and EtOH400ml into a three-necked flask, heat up to reflux, and stir for 3 hours , the heating was stopped, and the solvent was removed by rotary evaporation. use CH 2 Cl 2 Recrystallized with ether to obtain 50 g of white solid B.

[0074] in N 2 Under protection, compound B (20g, 64.5mmol), 2-cyclopentenone (25g, 304.5mmol) and anhydrous acetonitrile were added to the reaction flask, and triethylamine ( 7.17g, 70.9mmol), the dropwise addition was completed, and the reaction was carried out at room temperature under nitrogen protection for 24h. Add 100ml of water to the reaction solution to quench the reaction, extract the aqueous phase with ether, combine the organic phases, wash the organic phase with saturated brine, dry over anhydrous sodium sulfate, and ...

Embodiment 2

[0081] n is 0, R 1 When is ethyl, Z is benzyloxycarbonyl, the preparation of compound 1:

[0082]

[0083] in N 2 Under protection, compound E (2g, 6.04mmol), 1,2-ethanedithiol (0.8ml, 9.05mmol) and anhydrous dichloromethane (20ml) were added to the three-necked flask, and slowly added to the reaction solution at 20°C Add boron trifluoride ether (0.5ml, 3.13mmol) dropwise, after the dropwise addition, stir for 0.5h, add saturated sodium bicarbonate to quench the reaction, extract the aqueous phase with dichloromethane, combine the organic phases, and use saturated brine for the organic phases Washed, dried over anhydrous sodium sulfate, and spin-dried to obtain 2.6 g of light yellow oil. Column chromatography gave 2.3 g of compound 1 as a colorless oil, with a yield of 92%. m / z (M+Na + )430.01, 1 H NMR (400MHz, CDCl 3 )δ1.16-1.27(m,3H),1.69(s,1H),2.15-2.35(m,3H),2.81-2.86(m,1H),3.01-3.06(m,1H),3.28(s, 4H), 3.51-3.59(m, 1H), 3.75-3.82(m, 1H), 4.07-4.30(m, 3H), 5.04-5....

Embodiment 3

[0085] n is 1, R 1 When is ethyl, Z is benzyloxycarbonyl, the preparation of compound 1:

[0086]

[0087] in N 2 Under protection, compound E (0.5g, 1.51mmol), 1,3-propanedithiol (0.25ml, 2.26mmol) and anhydrous dichloromethane (8ml) were added to the three-necked flask, Slowly add boron trifluoride ether (0.2ml, 1.25mmol) dropwise, after the dropwise addition is complete, stir for 0.5h, add saturated sodium bicarbonate (20ml) to quench the reaction, extract the aqueous phase with dichloromethane, combine the organic phase, organic phase Washed with saturated brine, dried over anhydrous sodium sulfate, and spin-dried to obtain 0.6 g of light yellow oil. After purification by silica gel column chromatography, 0.5 g of compound 1 was obtained as a colorless oil with a yield of 93%. m / z (M+Na + )444.01, 1 HNMR (400MHz, CDCl 3 )δ1.16-1.27(m,3H),1.69(s,1H),1.88-1.97(m,1H),2.11-2.13(m,3H),2.31-2.41(m,1H),2.72-2.91( m,3H),2.92-3.01(m,2H),3.26-3.32(m,1H),3.62-3.79(m,2H),4.0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a telaprevir intermediate and a preparation method thereof. The telaprevir intermediate is a compound represented by 1. The preparation method of a telaprevir intermediate compound 2 comprises the following steps: in an organic solvent, under the effect of a desulfurization reagent, the compound 1 is subjected to a desulfurization reaction, such that the compound 2 can be prepared. R1 is C1-C6 straight-chain or branched-chain alkyl; n is 0, 1 or 2; Z is an amino protecting group. The telaprevir intermediate preparation method provided by the invention is simple and feasible.

Description

technical field [0001] The invention relates to the field of drug synthesis, in particular to a telaprevir intermediate and a preparation method thereof. Background technique [0002] Globally, the infection rate of hepatitis C virus (HCV) is about 3%, and the total number of infected people is about 200 million. Because of the high infection rate of HCV and the serious potential complications such as liver cirrhosis and liver cancer, HCV is a serious threat to human life and health. According to the Simmonds naming system, HCV can be divided into six main genotypes, namely I-VI, and each type can be divided into several subtypes (such as Ia, Ib, IIa, IIb, IIIa, IIIb, etc.). There are about 40 million HCV-infected people in my country, 69% of whom are type I infections (mainly type Ib). The current treatment of chronic hepatitis C is mainly the combination of pegylated interferon (PEG-IFNα) and ribavirin (RBV), which fails to produce sustained virological response in about...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D209/52C07D495/10
CPCY02P20/55C07D209/52C07D495/10
Inventor 张浩宇袁哲东杨玉雷姚旻
Owner SHANGHAI INST OF PHARMA IND